国际生物制品学杂志
國際生物製品學雜誌
국제생물제품학잡지
INTERNATIONAL JOURNAL OF BIOLOGICALS
2009年
1期
33-36
,共4页
干扰素Ⅱ型%肝纤维化%肺纤维化
榦擾素Ⅱ型%肝纖維化%肺纖維化
간우소Ⅱ형%간섬유화%폐섬유화
Interferon gamma%Liver fibrosis%Pulmonary fibrosis
实验室、动物试验和临床研究表明,干扰素γ(Interferon gamma,IFN-γ)对肝和肺纤维化有抑制作用.国内外学者报告用IFN-γ治疗各种原因引起的肝纤维化有效,临床症状明显改善,肝纤维化程度明显减轻.IFN-γ治疗特发性肺纤维化的初步结果显示,治疗后各种生物学指标有所改善,临床效果各家报道不一,多数学者认为IFN-γ治疗能降低病死率,对病情轻到中度的患者效果较好,用药时间应在1年以上.
實驗室、動物試驗和臨床研究錶明,榦擾素γ(Interferon gamma,IFN-γ)對肝和肺纖維化有抑製作用.國內外學者報告用IFN-γ治療各種原因引起的肝纖維化有效,臨床癥狀明顯改善,肝纖維化程度明顯減輕.IFN-γ治療特髮性肺纖維化的初步結果顯示,治療後各種生物學指標有所改善,臨床效果各傢報道不一,多數學者認為IFN-γ治療能降低病死率,對病情輕到中度的患者效果較好,用藥時間應在1年以上.
실험실、동물시험화림상연구표명,간우소γ(Interferon gamma,IFN-γ)대간화폐섬유화유억제작용.국내외학자보고용IFN-γ치료각충원인인기적간섬유화유효,림상증상명현개선,간섬유화정도명현감경.IFN-γ치료특발성폐섬유화적초보결과현시,치료후각충생물학지표유소개선,림상효과각가보도불일,다수학자인위IFN-γ치료능강저병사솔,대병정경도중도적환자효과교호,용약시간응재1년이상.
Animal experiments and clinical studies show the inhibiting effect of IFN-γ on hepatic and pulmonary fibrosis.Numerous research evidence suggests that IFN-γ is an effective therapy for hepatic fibrosis in improving clinical symptoms,and relieving hepatic fibrosis.Preliminary study results of IFN-γ for the treatment of idiopathic pulmonary fibrosis (IPF) show that various biomarkers are improved after IFN-γ therapy,and the case mortality is lowered.The therapeutic efficacy of IFN-γ has been demonstrated to be better in mild and moderate patients with LPF.The duration of IFN-β therapy should be more than one year.
